Ship-deficiency to increase megakaryocyte and platelet production

a megakaryocyte and platelet technology, applied in the field of ship deficiency to increase megakaryocyte and platelet production, can solve the problems of high platelet transfusion cost and patient at risk of infection by blood-borne pathogens, and achieve the effect of increasing the frequency of megakaryocyte progenitors

Inactive Publication Date: 2011-03-17
UNIV OF SOUTH FLORIDA
View PDF46 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0006]Mice that lack expression of a SHIP gene exhibit increased levels of both megakaryocyte progenitors and megakaryocytes in the bone marrow and spleens. In fact, megakaryocytes, the immediate precursor of platelets, are increased in the periphery of SHIP deficient mice approximately 10-100 fold. Therefore, methods that inhibit SHIP expression, its enzymatic activity or its signaling functions could be used in human patients to temporarily increase megakaryocytes and platelet numbers during periods when their platelets drop below numbers sufficient to promote normal blood clotting. In a similar way, SHIP expression or activity could be used to increase the yield of megakaryocytes, megakaryocyte progenitors or platelets in ex vivo expansion regimens that use human growth factors.

Problems solved by technology

This can require platelet transfusions that are very expensive and which place the patient at risk for infection by blood-borne pathogens (e.g. HIV, HepB and C).

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Ship-deficiency to increase megakaryocyte and platelet production
  • Ship-deficiency to increase megakaryocyte and platelet production
  • Ship-deficiency to increase megakaryocyte and platelet production

Examples

Experimental program
Comparison scheme
Effect test

example i

[0090]As shown in FIG. 1, SHIP1-deficiency increases the number of megakaryocytes (CD41+c-kit−) and megakaryocyte progenitors (CD41+c-kit+) in the hematopoietic compartment. Bone marrow, spleen and blood cells were stained for CD41, c-kit and a Lin panel (CD3, CD4, CD8, B220, Mac1, Gr1, Terr119). CD41 versus c-kit contour plots are shown after gating on Lin-cells in the indicated tissue. Increases in megakaryocyte progenitors (CD41+c-kit+) are evident in the bone marrow and spleen of the SHIP-deficient animal. Increased numbers of megakaryocytes (CD41+c-kit−) are found in the spleen and blood of the SHIP-deficient animal. Multiple SHIP1− / − and WT littermates were analyzed and the statistical significance of these increases is shown in FIG. 3.

example ii

[0091]Referring now to FIG. 2, SHIP1-deficiency increases the number of circulating platelets. Fluorescence-Activated Cell Sorter (FACS) analysis of peripheral blood cells stained with anti-CD41(megakaryocyte / platelet marker) from SHIP1-deficient (SHIP− / −) (A) and normal (SHIP+ / +) (B) mice. A, B. Platelets were initially quantitated based on their size (small forward and obtuse light scattering cells indicated by blue gates in A and B). C. The platelet identity of these small light scatter cells was confirmed by their expression of the CD41 marker.

example iii

[0092]Statistical analysis of increased megakaryocyte progenitors, megakaryocytes and platelets in SHIP-deficient (SHIP− / −) mice are depicted in FIG. 3. A, B. Absolute numbers of megakaryocyte progenitors as defined by CD41+c-kit+ expression (see FIG. 1) were significantly increased in sites of primary (bone marrow, BM) and extramedullary (spleen) sites of hematopoiesis in SHIP1-deficient mice as compared to normal mice (WT). C, D. Absolute megakaryocyte numbers are increased in peripheral hematopoietic tissues (spleen and blood) of SHIP1-deficient mice (see FIG. 1). E. Platelet numbers are increased in the blood of SHIP1-deficient mice relative to normal mice (see FIG. 2). All p-values were determined by a two-tailed Students' T-test. A p-value of less than 0.05 indicates the increased numbers for the above cell populations in SHIP-deficient mice (SHIP− / −) are highly significant as compared to normal mice.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
critical thresholdaaaaaaaaaa
frequencyaaaaaaaaaa
sizeaaaaaaaaaa
Login to view more

Abstract

A method of increasing megakaryocytes and platelet numbers in a patient comprising the step of inhibiting SHIP expression, including SHIP's enzymatic activity and signaling functions, whereby normal blood clotting is induced.

Description

CROSS-REFERENCE TO RELATED APPLICATION[0001]This application is a continuation of U.S. patent application Ser. No. 10 / 904,667, filed on Nov. 22, 2004, which claims the benefit of U.S. Provisional Application Ser. No. 60 / 481,677, filed Nov. 20, 2003, the disclosure of each of which is incorporated herein by reference in its entirety, including all figures, tables, amino acid and nucleic acid sequences.GOVERNMENT SUPPORT[0002]The subject matter of this application has been supported by research grants from the Leukemia and Lymphoma Society of America and the National Institutes of Health under grant numbers HL072523 and CA087989. Accordingly, the government has certain rights in this invention.BACKGROUND OF INVENTION[0003]Platelets are critical for blood clotting. However, in various human anemias, and in bone marrow transplant patients, platelets and the megakaryocytes they are derived from can drop below a critical threshold that is required to maintain normal clotting. This can req...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K35/12A61K31/7052C12N5/00A61P7/00
CPCC12N2501/70C12N5/0644A61P7/00
Inventor KERR, WILLIAM G.DESPONTS, CAROLINEPEREZ, LIA ELENA
Owner UNIV OF SOUTH FLORIDA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap